A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with AdvancedA Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with Advanced Solid Tumors (REFMAL 449) Solid Tumors (REFMAL 449)

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with AdvancedA Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with Advanced Solid Tumors (REFMAL 449) Solid Tumors (REFMAL 449)

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.